TGTX250110P35000
- 4.20
- 0.000.00%
TG Therapeutics Newsroom
TG Therapeutics Price Target Raised to $10 From $9 at BofA
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Express News | TG Therapeutics Inc : BofA Global Research Raises Price Objective to $10 From $9
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
Investors in TG Therapeutics (NASDAQ:TGTX) Have Seen Splendid Returns of 185% Over the Past Five Years
Will TG Therapeutics, Inc. (TGTX) Make You Rich In 2025?
Unusual Options Activity: XP, CRS and Others Attract Market Bets, XP V/OI Ratio Reaches 384.6
EST Dec 10th Afternoon Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?
TG Therapeutics to Participate in the Evercore HealthCONx Conference
TG Therapeutics Is Maintained at Overweight by JP Morgan
TG Therapeutics Analyst Ratings
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
A Closer Look at TG Therapeutics's Options Market Dynamics
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500
10 Health Care Stocks Whale Activity In Today's Session
Don't Ignore The Insider Selling In TG Therapeutics
TG Therapeutics | 10-Q: Q3 2024 Earnings Report
Subdued Growth No Barrier To TG Therapeutics, Inc. (NASDAQ:TGTX) With Shares Advancing 27%
TG Therapeutics Price Target Raised to $55.00/Share From $49.00 by HC Wainwright & Co.
TG Therapeutics Is Maintained at Buy by HC Wainwright & Co.